Genomic Analysis of Bevacizumab-induced Hypertension

Study ID Alternative Stable ID Type
phs001597 Case-Control

Study Description

Bevacizumab use in the treatment of cancer can lead to the development of hypertension in some patients, and high-grade toxicity can limit therapy or lead to cardiovascular complications. The factors that contribute to interindividual variability in blood pressure rise during bevacizumab treatment are not well understood. In the present study, whole exomes and flanking regulatory regions of candidate genes associated with vasodilation and blood pressure were sequenced in bevacizumab-treated subjects with the objective of identifying genes harboring multiple variants associated with severe, early-onset bevacizumab-induced hypertension.

Archive Link Archive Accession
dbGaP phs001597

Who archives the data?

There are no publications available